Tarsus Pharmaceuticals Inc
(NAS:TARS)
$
26.03
-0.33 (-1.25%)
Market Cap: 983.46 Mil
Enterprise Value: 715.45 Mil
PE Ratio: 0
PB Ratio: 3.57
GF Score: 53/100 Tarsus Pharmaceuticals Inc (TARS) Transcripts
- Q1 2024 Tarsus Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2024$37.35 (-1.79%)Earnings
- Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call TranscriptFeb 27, 2024$39.22 (+18.28%)Earnings
- Q3 2023 Tarsus Pharmaceuticals Inc Earnings Call TranscriptNov 09, 2023$15.57 (-5.86%)Earnings
- Tarsus Pharmaceuticals Inc To Discuss XDEMVY Approved For The Treatment Of Demodex Blepharitis Call TranscriptJul 25, 2023
- Tarsus Pharmaceuticals Inc To Discuss Creating the Next Blockbuster Category in Eye Care Call TranscriptJun 15, 2023
- Tarsus Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Tarsus Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Tarsus Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Tarsus Pharmaceuticals Inc To Discuss Revolutionizing Treatment For Demodex Blepharitis Patients Call TranscriptFeb 08, 2022
- Tarsus Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 08, 2021
- Tarsus Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Tarsus Pharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 22, 2021
- Tarsus Pharmaceuticals Inc Saturn-1 Pivotal Trial Topline Results Call TranscriptJun 21, 2021
- 1